JPM Conference, January 8, 2024
Nvidia is advancing its footprint in AI-powered drug discovery through new collaborations with biotech leaders Amgen and Recursion. These partnerships are designed to accelerate pharmaceutical R&D using Nvidia’s cutting-edge AI models and supercomputing capabilities.
Amgen’s deCode Genetics Taps Nvidia BioNeMo for Genomics AI
Amgen’s subsidiary, deCode Genetics, will leverage Nvidia’s BioNeMo platform, a generative AI framework tailored for drug discovery. Using BioNeMo and Nvidia’s supercomputers, deCode aims to develop foundational genomics models, enabling Amgen to customize these models with proprietary data for precision drug development.
Launch of MolMIM for Molecular Design
Nvidia unveiled MolMIM, a novel generative AI model designed to create small molecules in a controlled and optimized way. This model will be available via cloud-based APIs for BioNeMo, launching later this month. It opens a new frontier in molecular design for pharma companies and researchers.
Recursion Joins BioNeMo Platform with Phenom-Beta
Recursion will become the first external partner to integrate with Nvidia’s BioNeMo platform. Through its Phenom-Beta program—which translates cellular imaging data into actionable research insights—Recursion expands BioNeMo’s utility across the life sciences sector.
CEO Chris Gibson likened the development to a new era in drug discovery, saying the impact of Phenom-Beta could rival that of genomics in its transformative potential.
Recursion’s AI Leadership in Biopharma
Recursion is already a known leader in AI-powered drug development, maintaining high-profile partnerships with Bayer and Genentech (a subsidiary of Roche). While the company keeps key datasets proprietary, its AI programming is now accessible to the broader industry through BioNeMo.
Nvidia’s Healthcare Mission
Kimberly Powell, Nvidia’s VP of Healthcare, emphasized that the company’s goal is to empower biotech and pharmaceutical organizations to extract the full value from their data. With AI becoming essential in healthcare, Nvidia is positioning itself as a cornerstone technology provider to the life sciences.
Key Takeaways
- 🧬 Nvidia partners with Amgen’s deCode Genetics to develop genomics AI models.
- 🧪 Launch of MolMIM, a generative AI model for small molecule creation.
- 🧠 Recursion’s Phenom-Beta integrates with BioNeMo for wide industry use.
- 🤝 Nvidia reinforces its leadership in AI-driven pharmaceutical innovation.
As the convergence of biotech and AI accelerates, Nvidia continues to shape the next generation of drug discovery tools—empowering researchers and pharma companies with high-performance, intelligent platforms.
By